-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMUNEERING CORP - DOSING IN PHASE 2 TRIAL OF ATEBIMETINIB + LIBTAYO IN NSCLC EXPECTED IN 2H 2026

Reuters·03/06/2026 12:45:00

Please log in to view news